Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 8/2014

Open Access 01-06-2014 | Review Article

The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care

Authors: Rolf Hilgenfeld, Gerhard Seipke, Harald Berchtold, David R. Owens

Published in: Drugs | Issue 8/2014

Login to get access

Abstract

The epoch-making discovery of insulin heralded a new dawn in the management of diabetes. However, the earliest, unmodified soluble insulin preparations were limited by their short duration of action, necessitating multiple daily injections. Initial attempts to protract the duration of action of insulin involved the use of various additives, including vasoconstrictor substances, which met with limited success. The subsequent elucidation of the chemical and three-dimensional structure of insulin and its chemical synthesis and biosynthesis allowed modification of the insulin molecule itself, resulting in insulin analogs that are designed to mimic normal endogenous insulin secretion during both fasting and prandial conditions. Insulin glargine was the first once-daily, long-acting insulin analog to be introduced into clinical practice more than 10 years ago and is specifically designed to provide basal insulin requirements. It has a prolonged duration of action and no distinct insulin peak, making it suitable for once-daily administration and reducing the risk of nocturnal hypoglycemia that is seen with intermediate-acting insulins. Insulin glargine can be used in combination with prandial insulin preparations and non-insulin anti-diabetic agents according to individual requirements.
Appendix
Available only for authorised users
Literature
1.
Owens DR. Human insulin. UK, Europe, USA: MTP Press; 1986.
2.
Bliss M. The discovery of insulin: the inside story. Publ Am Inst Hist Pharm. 1997;16:93–9.PubMed
3.
4.
5.
Zajac J, Shrestha A, Patel P, Poretsky L. The main events in the history of diabetes mellitus. In: Poretsky L, editor. Principles of diabetes mellitus. New York: Springer Science + Business Media; 2010. p. 3–16.
6.
Himsworth HP. Diabetes mellitus: Its differentiation into insulin-sensitive and insulin-insensitive types. Lancet. 1936;227(5864):127–30.
7.
Papaspyros NS. Introduction. In: Verlag GT, editor. The history of diabetes mellitus. Stuttgart: Thieme; 1964. p. 1–10.
8.
von Mering J, Minkowski O. Diabetes mellitus nach Pankreasexstirpation. Arch Exp Path Pharmakol. 1890;26:371–87.
9.
Hédon E. Sur la consommation du sucre chez la chien après l’extirpation du pancreas. Arch Physiol Normal Pathol Vth Series. 1893;5:154–63.
10.
Minkowski O. Historical development of the theory of pancreatic diabetes by Oscar Minkowski, 1929: introduction and translation by Rachmiel Levine. Diabetes. 1989;38(1):1–6.PubMed
11.
Opie EL. The relation Oe diabetes mellitus to lesions of the Pancreas. Hyaline degeneration of the Islands Oe Langerhans. J Exp Med. 1901;5(5):527–40.PubMedCentralPubMed
12.
Opie EL. On the relation of chronic interstitial pancreatitis to the Islands of Langerhans and to diabetes melutus. J Exp Med. 1901;5(4):397–428.PubMedCentralPubMed
13.
Zülzer G. Ueber Versuche einer specifischen Fermenttherapie des Diabetes. Zeitschrift für die experimentelle Pathologie und Therapie. 1908;5(2):307–18.
14.
Paulesco NC. Action de l’extrait pancréatique injecté dans le sang, chez un animal diabétique. CR Seanc Soc Biol (Paris). 1921;85:555–9.
15.
Scott EL. On the influence of intravenous injections of an extract of the pancreas on experimental pancreatic diabetes. Am J Physiol. 1912;29:306–10.
16.
Kleiner IS. The action of intravenous injections of pancreas emulsions in experimental diabetes. J Biol Chem. 1919;40:153–70.
17.
Rennie J, Fraser T. The islets of Langerhans in relation to diabetes. Biochem J. 1907;2(1–2):7–19.PubMed
18.
Kimball CP, Murlin JR. Aqueous extracts of pancreas: III. Some precipitation reactions of insulin. J Biol Chem. 1923;58:337–46.
19.
Lasker SP, McLachlan CS, Wang L, Ali SMK, Jelinek HF. Discovery, treatment and management of diabetes. J Diabetol. 2010;1(1).
20.
Rosenfeld L. Insulin: discovery and controversy. Clin Chem. 2002;48(12):2270–88.PubMed
21.
de Leiva A, Brugues E, de Leiva-Perez A. The discovery of insulin: continued controversies after ninety years. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion. 2011;58(9):449–56. doi:10.​1016/​j.​endonu.​2011.​10.​001.
22.
Paulesco NC. Traitement du diabete. La Presse Medicale; 1924.
23.
Paulesco NC. Recherches sur le role du pancreas dans l’assimilation nutritive. Arch Int Physiol. 1921;17:85–109.
24.
Paulesco NC. Quelques reactions chimiques et physiques appliquees a l’extrait aqueux du pancreas pour le debarrasser des substances proteiques en exces. Arch Int Physiol. 1923;21:71–85.
25.
Paulesco NC. Divers procedes pour entroduire l’extrait pamcreatique dans l’organisme d’un animal diabetique. Arch Int Physiol. 1923;21:215–38.
26.
Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med. 1922;7:251–66.
27.
Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J. 1922;12(3):141–6.PubMedCentralPubMed
28.
Barron M. The relation of the islets of Langerhans to diabetes with special reference to cases of pancreatic lithiasis. Surg Gynecol Obstet. 1920;31:437–48.
29.
Banting FG, Best CH. Pancreatic extracts. J Lab Clin Med. 1922;7:464–72.
30.
Chamoun D, Choi D, Tavares AB, Udoff LC, Levitas E, Resnick CE, et al. Regulation of granulosa cell-derived insulin-like growth factor binding proteins (IGFBPs): role for protein kinase-C in the pre- and posttranslational modulation of IGFBP-4 and IGFBP-5. Biol Reprod. 2002;67(3):1003–12.PubMed
31.
von Horn H, Hwa V, Rosenfeld RG, Hall K, Teh BT, Tally M, et al. Altered expression of low affinity insulin-like growth factor binding protein related proteins in hepatoblastoma. Int J Mol Med. 2002;9(6):645–9.
32.
Garber AJ, Davidson JA, Krosnick A, Beaser RS, Anderson JH Jr. Impact of transfer from animal-source insulins to biosynthetic human insulin (rDNA E coli) in patients with diabetes mellitus. Clin Ther. 1991;13(5):627–36.PubMed
33.
Markussen J, Damgaard U, Jorgensen KH, Sorensen E, Thim L. Human monocomponent insulin. Chemistry and characteristics. Acta medica Scandinavica Supplementum. 1983;671:99–105.
34.
Thim L, Hansen MT, Sorensen AR. Secretion of human insulin by a transformed yeast cell. FEBS Lett. 1987;212(2):307–12 (pii: 0014-5793(87)81366-2).PubMed
35.
Nicol DS, Smith LF. Amino-acid sequence of human insulin. Nature. 1960;187:483–5.PubMed
36.
37.
Smith LF. Isolation of insulin from pancreatic extracts using carboxymethyl and diethylaminoethyl celluloses. Biochimica et biophysica acta. 1964;82:231–6.PubMed
38.
Kimmel JR, Pollock HG. Studies of human insulin from nondiabetic and diabetic pancreas. Diabetes. 1967;16(10):687–94.PubMed
39.
Brunfeldt K, Deckert T, Thomsen J. Human crystalline insulin from non-diabetic and diabetic patients. Acta endocrinologica. 1969;60(3):543–9.PubMed
40.
Shapcott D, O’Brien D. A method for the isolation of insulin from single human pancreas. Diabetes. 1970;19(11):831–6.PubMed
41.
World Health Organization. WHO Technical Report Series 565. Geneva1975.
42.
Kreines K. The use of various insulins in insulin allergy. Arch Intern Med (Chicago). 1965;116:167–71.
43.
Akre PR, Kirtley WR, Galloway JA. Comparative hypoglycemic response of diabetic subjects to human insulin or structurally similar insulins of animal source. Diabetes. 1964;13:135–43.PubMed
44.
Orskov H, Christensen NJ. Plasma disappearance rate of injected human insulin in juvenile diabetic, maturity-onset diabetic and nondiabetic subjects. Diabetes. 1969;18(10):653–9.PubMed
45.
Sonksen PH, Tompkins CV, Srivastava MC, Nabarro JD. A comparative study on the metabolism of human insulin and porcine proinsulin in man. Clin Sci Mol Med. 1973;45(5):633–54.PubMed
46.
Deckert T, Andersen OO, Grundahl E, Kerp L. Isoimmunization of man by recrystallized human insulin. Diabetologia. 1972;8(5):358–61.PubMed
47.
Sieber P, Kamber B, Hartmann A, Jöhl A, Riniker B, Rittel W. Totalsynthese von Humaninsulin unter gezielter Bildung der Disulfidbindungen. Vorläufige Mitteilung. Helvetica Chimica Acta. 1974;57(8):2617–21.
48.
Marki F, Albrecht W. Biological activity of synthetic human insulin. Diabetologia. 1977;13(4):293–5.PubMed
49.
Obermeier R, Geiger R. A new semisynthesis of human insulin. Hoppe-Seyler’s Zeitschrift fur physiologische Chemie. 1976;357(6):759–67.PubMed
50.
Homandberg GA, Mattis JA, Laskowski M Jr. Synthesis of peptide bonds by proteinases. Addition of organic cosolvents shifts peptide bond equilibria toward synthesis. Biochemistry. 1978;17(24):5220–7.PubMed
51.
Owens DR, Vora JP, Heding LG, Luzio S, Ryder RE, Atiea J, et al. Human, porcine and bovine ultralente insulin: subcutaneous administration in normal man. Diabetic Med: J Br Diabet Assoc. 1986;3(4):326–9.
52.
Best CH. Prolongation of insulin action. Ohio J Sci. 1937;37(6):362–77.
53.
Schlichtkrull J, Pingel M, Heding LG. Insulin preparations with prolonged effect. In: Hasselblatt A, Bruchhausen FV, editors. Handbook of experimental pharmacology. Berlin, Heidelberg, New York: Springer; 1975. p. 729–77.
54.
55.
Bauman L. Clinical experience with globin insulin. Am J Med Sci. 1939;198(4):475–81.
56.
Reiner L, Searle DS, Lang EH. On the hypoglycemic activity of globin insulin. J Pharmacol Exp Ther. 1939;67:330–40.
57.
Umber F, Stoerring FK, Foellmer W. Erfolge mit einem neuartigen Depot Insulin ohne Protaminzusatz (Surfen-Insulin). Klin Woch. 1938;17:443–6.
58.
Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49(12):2142–8.PubMed
59.
Chikama T, Nakamura M, Nishida T. Up-regulation of integrin alpha5 by a C-terminus four-amino-acid sequence of substance P (phenylalanine-glycine-leucine-methionine- amide) synergistically with insulin-like growth factor-1 in SV-40 transformed human corneal epithelial cells. Biochem Biophys Res Commun. 1999;255(3):692–7.PubMed
60.
Fujita-Yamaguchi Y, Hawke DH, Shively JE, Choi S. Partial amino acid sequence analyses of human placental insulin receptor. Protein Seq Data Anal. 1987;1(1):3–6.PubMed
61.
Matsumoto S, Isogai A, Suzuki A. N-terminal amino acid sequence of an insect neurohormone, melanization and reddish coloration hormone (MRCH): heterogeneity and sequence homology with human insulin-like growth factor II. FEBS Lett. 1985;189(1):115–8.PubMed
62.
Bell SC, Keyte JW. N-terminal amino acid sequence of human pregnancy-associated endometrial alpha 1-globulin, an endometrial insulin-like growth factor (IGF) binding protein–evidence for two small molecular weight IGF binding proteins. Endocrinology. 1988;123(2):1202–4.PubMed
63.
Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem. 1978;253(8):2769–76.PubMed
64.
Krayenbuhl C, Rosenberg T. Crystalline protamine insulin. Rep Steno Mem Hosp Nord Insulinlab. 1946;1:60–73.
65.
66.
Hallas-Moller K, Jersild M, Petersen K, Schlichtkrull J. The lente insulins, insulin-zinc suspensions. Danish Med Bull. 1954;1(5):132–42.PubMed
67.
Whitehouse FW, Lowrie WL, Redfern E, Bryan JB. The lente insulin triad, with emphasis on the use of “lente combinations”. Ann Intern Med. 1961;55:894–902.PubMed
68.
Galloway JA, Bressler R. Insulin treatment in diabetes. Med Clin N Am. 1978;62(4):663–80.PubMed
69.
White JR Jr., Campbell RK, Hirsch I. Insulin analogues: new agents for improving glycemic control. Postgrad Med. 1997;101(2):58–60, 3–5, 70.
70.
Bergenstal RM, Rosenstock J, Arakaki RF, Prince MJ, Qu Y, Sinha VP, et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care. 2012;35(11):2140–7. doi:10.​2337/​dc12-0060.PubMedCentralPubMed
71.
Rosenstock J, Bergenstal RM, Blevins TC, Morrow LA, Prince MJ, Qu Y, et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care. 2013;36(3):522–8. doi:10.​2337/​dc12-0067.PubMedCentralPubMed
72.
Sanger F, Tuppy H. The amino-acid sequence in the phenylalanyl chain of insulin. 2. The investigation of peptides from enzymic hydrolysates. Biochem J. 1951;49(4):481–90.PubMedCentralPubMed
73.
Sanger F, Tuppy H. The amino-acid sequence in the phenylalanyl chain of insulin. I. The identification of lower peptides from partial hydrolysates. Biochem J. 1951;49(4):463–81.PubMedCentralPubMed
74.
Adams MJ, Blundell TL, Dodson EJ, Dodson GG, Vijayan M, Bakar EN, et al. Structure of rhombohedral 2 zinc insulin crystals. Nature. 1969;224(5218):491–5.
75.
Vajo Z, Duckworth WC. Genetically engineered insulin analogs: diabetes in the new millenium. Pharmacol Rev. 2000;52(1):1–9.PubMed
76.
Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature. 1988;333(6174):679–82. doi:10.​1038/​333679a0.PubMed
77.
Markussen J, Diers I, Engesgaard A, Hansen MT, Hougaard P, Langkjaer L, et al. Soluble, prolonged-acting insulin derivatives. II. Degree of protraction and crystallizability of insulins substituted in positions A17, B8, B13, B27 and B30. Protein Eng. 1987;1(3):215–23.PubMed
78.
Markussen J, Diers I, Hougaard P, Langkjaer L, Norris K, Snel L, et al. Soluble, prolonged-acting insulin derivatives. III. Degree of protraction, crystallizability and chemical stability of insulins substituted in positions A21, B13, B23, B27 and B30. Protein Eng. 1988;2(2):157–66.PubMed
79.
Markussen J, Hougaard P, Ribel U, Sorensen AR, Sorensen E. Soluble, prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain. Protein Eng. 1987;1(3):205–13.PubMed
80.
Geiger R. Chemie des Insulins. Chemiker Zeitung. 1976;100:111–29.
81.
Jorgensen S, Vaag A, Langkjaer L, Hougaard P, Markussen J. NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue. Bmj. 1989;299(6696):415–9.PubMedCentralPubMed
82.
Zeuzem S, Stahl E, Jungmann E, Zoltobrocki M, Schoffling K, Caspary WF. In vitro activity of biosynthetic human diarginylinsulin. Diabetologia. 1990;33(2):65–71.PubMed
83.
Monti LD, Poma R, Caumo A, Stefani I, Picardi A, Sandoli EP, et al. Intravenous infusion of diarginylinsulin, an insulin analogue: effects on glucose turnover and lipid levels in insulin-treated type II diabetic patients. Metab: Clin Exp. 1992;41(5):540–4.
84.
Kemmler W, Peterson JD, Steiner DF. Studies on the conversion of proinsulin to insulin. I. Conversion in vitro with trypsin and carboxypeptidase B. J Biol Chem. 1971;246(22):6786–91.PubMed
85.
Grau U. Inventor Hoechst Aktiengesellschaft, assignee. Pharmaceutical agent for the treatment of diabetes mellitus United States1984.
86.
Rhodes CJ. Processing of the insulin molecule. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes mellitus: a fundamental and clinical text. 3rd ed. London: Lippincott Williams & Wilkins; 2004.
87.
88.
Derewenda U, Derewenda Z, Dodson EJ, Dodson GG, Reynolds CD, Smith GD, et al. Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer. Nature. 1989;338(6216):594–6. doi:10.​1038/​338594a0.PubMed
89.
Brange J, Skelbaek-Pedersen B, Lankjaer L, Damgaar U, Ego H, Havelund S, et al. Galenics of insulin preparations. In: Berger M, editor. Subcutaneous insulin therapy. Berlin, Heidelberg: Springer; 1985.
90.
Seipke G, Geisen K, Neubauer H-P, Pittius C, Rosskamp R, Schwabe D. New insulin preparations with prolonged action profiles: A21-modified arginine insulins [abstract]. Diabetologia. 1992;35(Suppl. 1):A4.
91.
Seipke G, Berchtold H, Geisen K, Hilgenfeld R, Rosskamp R. HOE 901: a new insulin with prolonged action [abstract]. Eur J Endocrinol. 1995;132(Suppl. 1):25.
92.
Hilgenfeld R, Sicker T, Dörschug M, Obermeier R, Geisen K, Seipke G, et al. Controlling insulin bioavailability by crystal contact engineering. Diabetologia. 1992;35(Supplement):A193.
93.
Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care. 2000;23(2):157–62.PubMed
94.
HOE 901/2004 Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diabet Med: J Br Diabet Assoc. 2003;20(7):545–51.
95.
Rosenstock J, Park G, Zimmerman J, Group, USIGTDI. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care. 2000;23(8):1137–42.PubMed
96.
Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care. 2000;23(6):813–9.PubMed
97.
Owens DR. Optimizing treatment strategies with insulin glargine in Type 2 diabetes. Expert Rev Endocrinol Metab. 2012;7(4):377–93.
98.
Bolli GB, Frick A, Schmidt R, Eisenblaetter T, Becker R. Plasma concentrations of insulin glargine and its metabolites after SC injection of glargine in subjects with type 1 diabetes. ADA 71st Scientific Sessions; June 24–28, 2011; San Diego, CA. Abstract 71-OR2011.
99.
Lucidi P, Portcellati F, Rossetti P, Candeloro P, Andreoli AM, Frick A et al. Metabolism of insulin glargine after subcutaneous injection of therapeutic dose in type 2 diabetes mellitus. ADA 71st Scientific Sessions; June 24–28, 2011; San Diego, CA. Abstract 1092-P2011.
100.
Werner U, Schmidt R, Blair E, Renna SM, Tennagels N. The molecular mechanism of insulin glargine metabolism in vivo. ADA 72nd Scientific Sessions; June 8–12, 2012; Philadelphia, PA. Abstract 1645-P2012.
101.
Porcellati F, Rossetti P, Ricci NB, Pampanelli S, Torlone E, Campos SH, et al. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. Diabetes Care. 2007;30(5):1261–3. doi:10.​2337/​dc06-2208.PubMed
102.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–79. doi:10.​2337/​dc12-0413.PubMedCentralPubMed
103.
Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23(5):644–9.PubMed
104.
Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000;23(5):639–43.PubMed
105.
106.
107.
108.
109.
110.
Investigators OT, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28. doi:10.​1056/​NEJMoa1203858.
111.
Ashwell SG, Gebbie J, Home PD. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Diabet Med: J Br Diabet Assoc. 2006;23(1):46–52. doi:10.​1111/​j.​1464-5491.​2005.​01726.​x.
112.
Riddle MC, Rosenstock J, Gerich J, Insulin Glargine Study I. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–6.PubMed
113.
Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study. Diabetes, Obes Metab. 2011;13(11):1020–7. doi:10.​1111/​j.​1463-1326.​2011.​01459.​x.
114.
Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30(11):1976–87. doi:10.​1016/​j.​clinthera.​2008.​11.​001.PubMed
115.
116.
Riddle M, Home P, Marre M, Niemoeller E, Ping L, Rosenstock J. Efficacy and safety of once-daily lixisenatide in Type 2 diabetes insufficiently controlled with basal insulin ± metformin: GetGoal-L study. Diabetes. 2012;61(Supplement 1):983-P (A251).
117.
Rosenstock J, Forst T, Aronson R, Sau-que-reyna L, Souhami E, Ping L et al. Efficacy and safety of once-daily lixisenatide added on to titrated glargine plus oral agents in Type 2 diabetes: GetGoal-Duo 1 Study. Diabetes. 2012;61(Supplement 1):62-OR (A18).
118.
Seino Y, Min KW, Niemoeller E, Takami A, Investigators EG-LAS. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes, Obes Metab. 2012;14(10):910–7. doi:10.​1111/​j.​1463-1326.​2012.​01618.​x.
119.
Petznick A. Insulin management of Type 2 diabetes mellitus. Am Fam Physician. 2011;84:183–90.PubMed
120.
Brandle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of insulin glargine compares with NPH insulin nased on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther. 2007;45:203–20.PubMed
121.
Pfohl M, Schädlich PK, Dippel FW, Koltermann KC. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany. J Med Econ. 2012;15(Suppl 2):14–27.PubMed
122.
Gordon J, Evans M, McEwan P, Bain S, Vora J. Evaluation of insulin use and value for money in Type 2 diabetes in the United Kingdom. Diabetes Ther. 2013;4:51–66.PubMedCentralPubMed
123.
124.
Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diab Obes Metab. 2009;11:372–8.
125.
Wang L, Wei W, Miao R, et al. Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study. BMJ Open. 2013;3:e002348.PubMedCentralPubMed
126.
Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Munoz-Torres M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498–507. doi:10.​1016/​S0140-6736(12)60205-0.PubMed
127.
Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1489–97. doi:10.​1016/​S0140-6736(12)60204-9.PubMed
128.
Yang Y, Hua QX, Liu J, Shimizu EH, Choquette MH, Mackin RB, et al. Solution structure of proinsulin: connecting domain flexibility and prohormone processing. J Biol Chem. 2010;285(11):7847–51. doi:10.​1074/​jbc.​C109.​084921
129.
Smith GD, Pangborn WA, Blessing RH. The structure of T6 human insulin at 1.0 A resolution. Acta Crystallogr D Biol Crystallogr. 2003;59:474–82.
130.
Metadata
Title
The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care
Authors
Rolf Hilgenfeld
Gerhard Seipke
Harald Berchtold
David R. Owens
Publication date
01-06-2014
Publisher
Springer International Publishing
Published in
Drugs / Issue 8/2014
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0226-4

Other articles of this Issue 8/2014

Drugs 8/2014 Go to the issue

Review Article

First-Line and Maintenance Therapy for Ovarian Cancer: Current Status and Future Directions

R&D Insight Report

Luseogliflozin: First Global Approval

Review Article

Pharmacokinetics and Pharmacodynamics of Antifungals in Children: Clinical Implications

Leading Article

Next-Generation Phosphate Binders: Focus on Iron-Based Binders

R&D Insight Report

Tofogliflozin: First Global Approval

R&D Insight Report

Albiglutide: First Global Approval